Survival in patients with metastatic breast cancer: Analysis of randomized studies comparing oral aromatase inhibitors versus megestrol

Anti-Cancer Drugs

Volumn 11, Issue 9, 2000, Pages 701-706

  Messori, A ^a   Cattel, F ^a   Trippoli, S ^a   Vaiani, M ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Aromatase inhibitors; Breast cancer; Survival

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; MEGESTROL;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; META ANALYSIS; METASTASIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; MEGESTROL; NEOPLASM METASTASIS; NITRILES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TRIAZOLES;

EID: 0033673399     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200010000-00005     Document Type: Article

References (25)

1. A randomized II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma
2. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: A phase II study
3. Multicenter, phase H trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
4. Letrozole, a new oral aromatase inhibitor for advanced breast cancer
5. Anastrozole versus megestrole acetate in the treatment of postmenopausal women with advanced breast carcinoma
6. Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
7. Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multi-institutional trials
8. Randomized phase III trial comparing the new potent and selective third generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
9. Aromatase inhibitors in the treatment of postmenopausal breast cancer
10. The third-generation non steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
11. Meta-analysis of the literature or of individual patient data: Is there a difference?
12. A comparison of meta-analytic results using literature vs individual patient data: Paternal cell immunization for recurrent miscarriage
13. Comparison of effect estimates from a meta-analysis of summary data from published studies and from a meta-analysis using individual patient data for ovarian cancer studies
14. From science to practice: Meta-analysis using individual patient data are needed
15. Meta-analysis of clinical trials based on censored end-points: Simplified theory and implementation of the statistical algorithms on a microcomputer
16. Survival curve fitting using the Gompertz function: A methodology for conducting cost-effectiveness analyses on mortality data
17. A retrospective costeffectiveness analysis of interferon as adjuvant therapy in high-risk resected cutaneous melanoma
18. Cost-effectiveness of riluzole in amyotrophic lateral sclerosis
19. Recommendations of the Panel on Cost-effectiveness in Health and Medicine
20. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
21. Effectiveness of 5-aminosalicylic acid enemas for maintaining remission in patients with left-sided ulcerative colitis: A meta- and economic analysis
22. Effectiveness of 5-aminosalicylic acid (5-ASA) for maintaining remission in patients with Crohn's disesase: A meta-analysis
23. Effect of recombinant or lymphoblastoid alpha interferon on ALT in patients with chronic hepatitis C or chronic non-A non-B hepatitis: A meta-analysis
24. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: A meta-analysis
25. Retrospective survival analysis and cost-effectiveness evaluation of second allogeneic bone marrow transplantation in patients with acute leukemia